RLAY vs. ALLO, FATE, VIR, FPRX, SWTX, ACLX, APGE, DNLI, IOVA, and IMCR
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Vir Biotechnology (VIR), Five Prime Therapeutics (FPRX), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), and Immunocore (IMCR). These companies are all part of the "medical" sector.
Relay Therapeutics (NASDAQ:RLAY) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
Allogene Therapeutics has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
In the previous week, Allogene Therapeutics had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 9 mentions for Allogene Therapeutics and 6 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat Allogene Therapeutics' score of 0.30 indicating that Relay Therapeutics is being referred to more favorably in the media.
Relay Therapeutics has a net margin of -1,263.49% compared to Allogene Therapeutics' net margin of -223,139.98%. Relay Therapeutics' return on equity of -42.66% beat Allogene Therapeutics' return on equity.
Allogene Therapeutics received 232 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 64.83% of users gave Allogene Therapeutics an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
Relay Therapeutics currently has a consensus target price of $22.20, suggesting a potential upside of 246.33%. Allogene Therapeutics has a consensus target price of $9.95, suggesting a potential upside of 298.00%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Relay Therapeutics.
97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by insiders. Comparatively, 24.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Allogene Therapeutics beats Relay Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
